PLoS Medicine
(Accessed 11 December 2011)
http://www.plosmedicine.org/article/browse.action?field=date

The Primacy of Public Health Considerations in Defining Poor Quality Medicines
Paul N. Newton, Abdinasir A. Amin, Chris Bird, Phillip Passmore, Graham Dukes, Göran Tomson, Bright Simons, Roger Bate, Philippe J. Guerin, Nicholas J. White Essay, published 06 Dec 2011
doi:10.1371/journal.pmed.1001139

Summary Points
– Poor quality essential medicines, both substandard and counterfeit, are serious but neglected public health problems. Anti-infective medicines are particularly afflicted.

– Unfortunately, attempts to improve medicine quality have been hampered by confusion and controversy over definitions. For counterfeit (or falsified) medicines, this has arisen from perceived differences between public health and intellectual property approaches to the problem.

– We argue that public health, and not intellectual property or trade issues, should be the prime consideration in defining and combating counterfeit medicines, and that the World Health Organization (WHO) should be encouraged and supported to take a more prominent role in improving the world’s medicine quality and supply.

– An international treaty on medicine quality, under WHO auspices, could be an important step forward in the struggle against both substandard and counterfeit (or falsified) medicines.